Anti-angiogenic gene therapy in the treatment of malignant gliomas

Neuroscience Letters

Volumn 527, Issue 2, 2012, Pages 62-70

  Gatson, NaTosha N ^a   Chiocca, E Antonio ^a   Kaur, Balveen ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Astrocytoma; Brain tumor; Glioma; Oncolytic virus; Vasculostatin; VEGF

Indexed keywords

ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CD36 ANTIGEN; ENDOSTATIN; PARVOVIRUS VECTOR; PROTEIN P53; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 8; RECOMBINANT THROMBOCYTE FACTOR 4; TEMOZOLOMIDE; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADENO ASSOCIATED VIRUS; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CELL MIGRATION; COLORECTAL CARCINOMA; DRUG DISTRIBUTION; DRUG TOLERANCE; ENZYME ACTIVITY; GENE EXPRESSION; GLIOBLASTOMA; HEALTH CARE UTILIZATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SURVIVAL TIME;

BRAIN NEOPLASMS; GENETIC THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84866744776     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.08.001     Document Type: Review

References (147)

1. Abe T., Terada K., Wakimoto H., Inoue R., Tyminski E., Bookstein R., Basilion J.P., Chiocca E.A. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Research 2003, 63:2300-2305.
2. Abounader R., Lal B., Luddy C., Koe G., Davidson B., Rosen E.M., Laterra J. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB Journal 2002, 16:108-110.
3. Aghi M., Chiocca E.A. Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Molecular Therapy 2005, 12:994-1005.
4. Aghi M., Cohen K.S., Klein R.J., Scadden D.T., Chiocca E.A. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Research 2006, 66:9054-9064.
5. Aghi M., Visted T., Depinho R.A., Chiocca E.A. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 2008, 27:4249-4254.
6. Alvarez-Breckenridge C.A., Yu J., Kaur B., Caligiuri M.A., Chiocca E.A. Deciphering the multifaceted relationship between oncolytic viruses and natural killer cells. Advances in Virology 2012, 2012:702839.
7. Barnett F.H., Scharer-Schuksz M., Wood M., Yu X., Wagner T.E., Friedlander M. Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure. Gene Therapy 2004, 11:1283-1289.
8. Bergen J.M., Park I.K., Horner P.J., Pun S.H. Nonviral approaches for neuronal delivery of nucleic acids. Pharmaceutical Research 2008, 25:983-998.
9. Bergers G., Benjamin L.E., Tumorigenesis the angiogenic switch. Nature Reviews Cancer 2003, 3:401-410.
10. Bhat R., Steinman L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron 2009, 64:123-132.
11. Bodles-Brakhop A.M., Heller R., Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Molecular Therapy 2009, 17:585-592.
12. Castellani P., Dorcaratto A., Siri A., Zardi L., Viale G.L. Tenascin distribution in human brain tumours. Acta Neurochirurgica 1995, 136:44-50.
13. Charles N.A., Holland E.C., Gilbertson R., Glass R., Kettenmann H. The brain tumor microenvironment. Glia 2011, 59:1169-1180.
14. Chiocca E.A. The host response to cancer virotherapy. Current Opinion in Molecular Therapeutics 2008, 10:38-45.
15. Chiocca E.A., Choi B.B., Cai W.Z., DeLuca N.A., Schaffer P.A., DiFiglia M., Breakefield X.O., Martuza R.L. Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biologist 1990, 2:739-746.
16. Chiu T.L., Peng C.W., Wang M.J. Enhanced anti-glioblastoma activity of microglia by AAV2-mediated IL-12 through TRAIL and phagocytosis in vitro. Oncology Reports 2011, 25:1373-1380.
17. Cork S.M., Kaur B., Devi N.S., Cooper L., Saltz J.H., Sandberg E.M., Kaluz S., Van Meir E.G. A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40kDa vasculostatin from tumor suppressor BAI1. Oncogene 2012.
18. Couzin-Frankel J., Ogale Y. FDA once on 'fast track,' avastin now derailed. Science 2011, 333:143-144.
19. Crocker M., Ashley S., Giddings I., Petrik V., Hardcastle A., Aherne W., Pearson A., Bell B.A., Zacharoulis S., Papadopoulos M.C. Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro-Oncology 2011, 13:99-108.
20. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265:1582-1584.
21. Davids M.S., Charlton A., Ng S.S., Chong M.L., Laubscher K., Dar M., Hodge J., Soong R., Goh B.C. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. Journal of Clinical Oncology 2009, 27:e97-e100.
22. Dixelius J., Larsson H., Sasaki T., Holmqvist K., Lu L., Engstrom A., Timpl R., Welsh M., Claesson-Welsh L. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000, 95:3403-3411.
23. Dmitrieva N., Yu L., Viapiano M., Cripe T.P., Chiocca E.A., Glorioso J.C., Kaur B. Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clinical Cancer Research 2011, 17:1362-1372.
24. Duda D.G., Sunamura M., Lozonschi L., Yokoyama T., Yatsuoka T., Motoi F., Horii A., Tani K., Asano S., Nakamura Y., Matsuno S. Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis. British Journal of Cancer 2002, 86:490-496.
25. Eisman R., Surrey S., Ramachandran B., Schwartz E., Poncz M. Structural and functional comparison of the genes for human platelet factor 4 and PF4alt. Blood 1990, 76:336-344.
26. Folkman J., Klagsbrun M. Angiogenic factors. Science 1987, 235:442-447.
27. Frampton A.R., Goins W.F., Nakano K., Burton E.A., Glorioso J.C. HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Therapy 2005, 12:891-901.
28. Friedl P., Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Research 2008, 68:7247-7249.
29. Friedman A., Tian J.P., Fulci G., Chiocca E.A., Wang J. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Research 2006, 66:2314-2319.
30. Fukumura D., Jain R.K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. Journal of Cellular Biochemistry 2007, 101:937-949.
31. Fukushima Y., Oshika Y., Tsuchida T., Tokunaga T., Hatanaka H., Kijima H., Yamazaki H., Ueyama Y., Tamaoki N., Nakamura M. Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer. International Journal of Oncology 1998, 13:967-970.
32. Fulci G., Dmitrieva N., Gianni D., Fontana E.J., Pan X., Lu Y., Kaufman C.S., Kaur B., Lawler S.E., Lee R.J., Marsh C.B., Brat D.J., van Rooijen N., Stemmer-Rachamimov A.O., Hochberg F.H., Weissleder R., Martuza R.L., Chiocca E.A. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Research 2007, 67:9398-9406.
33. Gentilini G., Kirschbaum N.E., Augustine J.A., Aster R.H., Visentin G.P. Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21 (Cip1/WAF1). Blood 1999, 93:25-33.
34. Giese A., Loo M.A., Norman S.A., Treasurywala S., Berens M.E. Contrasting migratory response of astrocytoma cells to tenascin mediated by different integrins. Journal of Cell Science 1996, 109(Pt 8):2161-2168.
35. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., Bouck N.P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:6624-6628.
36. Grandi P., Peruzzi P., Reinhart B., Cohen J.B., Chiocca E.A., Glorioso J.C. Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Review of Neurotherapeutics 2009, 9:505-517.
37. Griscelli F., Li H., Cheong C., Opolon P., Bennaceur-Griscelli A., Vassal G., Soria J., Soria C., Lu H., Perricaudet M., Yeh P. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:6698-6703.
38. Grossman R., Tyler B., Hwang L., Zadnik P., Lal B., Javaherian K., Brem H. Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin. Journal of Neurosurgery 2011, 115:1139-1146.
39. Guo S.W., Che H.M., Li W.Z. Anti-tumor effect of lentivirus-mediated gene transfer of alphastatin on human glioma. Cancer Science 2011, 102:1038-1044.
40. Han L., Zhang A., Wang H., Pu P., Jiang X., Kang C., Chang J. Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Human Gene Therapy 2010, 21:417-426.
41. Hardcastle J., Kurozumi K., Dmitrieva N., Sayers M.P., Ahmad S., Waterman P., Weissleder R., Chiocca E., Kaur B. Vasculostatin expression mediated by oncolytic HSV inhibits tumor growth and angiogenesis. Molecular Therapy 2010, 18:285-294.
42. Hardcastle J., Kurozumi K., Dmitrieva N., Sayers M.P., Ahmad S., Waterman P., Weissleder R., Chiocca E.A., Kaur B. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Molecular Therapy 2010, 18:285-294.
43. Hatanaka H., Oshika Y., Abe Y., Yoshida Y., Hashimoto T., Handa A., Kijima H., Yamazaki H., Inoue H., Ueyama Y., Nakamura M. Vascularization is decreased in pulmonary adenocarcinoma expressing brain-specific angiogenesis inhibitor 1 (BAI1). International Journal of Molecular Medicine 2000, 5:181-183.
44. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine 2005, 352:997-1003.
45. Heidenreich R., Machein M., Nicolaus A., Hilbig A., Wild C., Clauss M., Plate K.H., Breier G. Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. International Journal of Cancer 2004, 111:348-357.
46. Higuchi M., Ohnishi T., Arita N., Hiraga S., Hayakawa T. Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis. Acta Neuropathologica 1993, 85:481-487.
47. Hoshi M., Harada A., Kawase T., Uyemura K., Yazaki T. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy. Cancer Gene Therapy 2000, 7:799-805.
48. Hutson T.E., Davis I.D., Machiels J.P., De Souza P.L., Rottey S., Hong B.F., Epstein R.J., Baker K.L., McCann L., Crofts T., Pandite L., Figlin R.A. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2010, 28:475-480.
49. Im S.A., Gomez-Manzano C., Fueyo J., Liu T.J., Ke L.D., Kim J.S., Lee H.Y., Steck P.A., Kyritsis A.P., Yung W.K. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Research 1999, 59:895-900.
50. Izutsu T., Konda R., Sugimura J., Iwasaki K., Fujioka T. Brain-specific angiogenesis inhibitor 1 is a putative factor for inhibition of neovascular formation in renal cell carcinoma. Journal of Urology 2011, 185:2353-2358.
51. Kambara H., Okano H., Chiocca E.A., Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Research 2005, 65:2832-2839.
52. Kamoun W.S., Ley C.D., Farrar C.T., Duyverman A.M., Lahdenranta J., Lacorre D.A., Batchelor T.T., di Tomaso E., Duda D.G., Munn L.L., Fukumura D., Sorensen A.G., Jain R.K. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. Journal of Clinical Oncology 2009, 27:2542-2552.
53. Kang X., Xiao X., Harata M., Bai Y., Nakazaki Y., Soda Y., Kurita R., Tanaka T., Komine F., Izawa K., Kunisaki R., Setoyama M., Nishimori H., Natsume A., Sunamura M., Lozonshi L., Saitoh I., Tokino T., Asano S., Nakamura Y., Tani K. Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas. Cancer Gene Therapy 2006, 13:385-392.
54. Kang Y.A., Shin H.C., Yoo J.Y., Kim J.H., Kim J.S., Yun C.O. Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus. Molecular Therapy 2008, 16:1033-1040.
55. Kaur B., Brat D.J., Calkins C.C., Van Meir E.G. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. American Journal of Pathology 2003, 162:19-27.
56. Kaur B., Brat D.J., Devi N.S., Van Meir E.G. Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 2005, 24:3632-3642.
57. Kaur B., Cork S.M., Sandberg E.M., Devi N.S., Zhang Z., Klenotic P.A., Febbraio M., Shim H., Mao H., Tucker-Burden C., Silverstein R.L., Brat D.J., Olson J.J., Van Meir E.G. Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Research 2009, 69:1212-1220.
58. Kaur B., Cripe T.P., Chiocca E.A. Buy one get one free: armed viruses for the treatment of cancer cells and their microenvironment. Current Gene Therapy 2009, 9:341-355.
59. Kim Y.M., Jang J.W., Lee O.H., Yeon J., Choi E.Y., Kim K.W., Lee S.T., Kwon Y.G. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Research 2000, 60:5410-5413.
60. Kirsch M., Strasser J., Allende R., Bello L., Zhang J., Black P.M. Angiostatin suppresses malignant glioma growth in vivo. Cancer Research 1998, 58:4654-4659.
61. Kong Y., Le Y. Toll-like receptors in inflammation of the central nervous system. International Immunopharmacology 2011, 11:1407-1414.
62. Kudo S., Konda R., Obara W., Kudo D., Tani K., Nakamura Y., Fujioka T. Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma. Oncology Reports 2007, 18:785-791.
63. Kurozumi K., Hardcastle J., Thakur R., Yang M., Christoforidis G., Fulci G., Hochberg F.H., Weissleder R., Carson W., Chiocca E.A., Kaur B. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. Journal of the National Cancer Institute 2007, 99:1768-1781.
64. Lamfers M.L., Gianni D., Tung C.H., Idema S., Schagen F.H., Carette J.E., Quax P.H., Van Beusechem V.W., Vandertop W.P., Dirven C.M., Chiocca E.A., Gerritsen W.R. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Research 2005, 65:9398-9405.
65. Lane H.A., Lebwohl D. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. Seminars in Oncology 2006, 33:S18-S25.
66. Lawler J.W., Slayter H.S., Coligan J.E. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. Journal of Biological Chemistry 1978, 253:8609-8616.
67. Lee J.H., Koh J.T., Shin B.A., Ahn K.Y., Roh J.H., Kim Y.J., Kim K.K. Comparative study of angiostatic and anti-invasive gene expressions as prognostic factors in gastric cancer. International Journal of Oncology 2001, 18:355-361.
68. Lee T.Y., Muschal S., Pravda E.A., Folkman J., Abdollahi A., Javaherian K. Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood 2009, 114:1987-1998.
69. Liu J., Xu X., Feng X., Zhang B., Wang J. Adenovirus-mediated delivery of bFGF small interfering RNA reduces STAT3 phosphorylation and induces the depolarization of mitochondria and apoptosis in glioma cells U251. Journal of Experimental and Clinical Cancer Research 2011, 30:80.
70. Liu T.C., Zhang T., Fukuhara H., Kuroda T., Todo T., Canron X., Bikfalvi A., Martuza R.L., Kurtz A., Rabkin S.D. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clinical Cancer Research 2006, 12:6791-6799.
71. Liu T.C., Zhang T., Fukuhara H., Kuroda T., Todo T., Martuza R.L., Rabkin S.D., Kurtz A. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Molecular Therapy 2006, 14:789-797.
72. Lorico A., Mercapide J., Solodushko V., Alexeyev M., Fodstad O., Rappa G. Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma. Cancer Gene Therapy 2008, 15:605-615.
73. Los M., Roodhart J.M., Voest E.E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007, 12:443-450.
74. Lu W., Zhou X., Hong B., Liu J., Yue Z. Suppression of invasion in human U87 glioma cells by adenovirus-mediated co-transfer of TIMP-2 and PTEN gene. Cancer Letters 2004, 214:205-213.
75. Ma H.I., Guo P., Li J., Lin S.Z., Chiang Y.H., Xiao X., Cheng S.Y. Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Research 2002, 62:756-763.
76. Ma H.I., Lin S.Z., Chiang Y.H., Li J., Chen S.L., Tsao Y.P., Xiao X. Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Therapy 2002, 9:2-11.
77. Maione T.E., Gray G.S., Petro J., Hunt A.J., Donner A.L., Bauer S.I., Carson H.F., Sharpe R.J. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247:77-79.
78. Markert J.M., Cody J.J., Parker J.N., Coleman J.M., Price K.H., Kern E.R., Quenelle D.C., Lakeman A.D., Schoeb T.R., Palmer C.A., Cartner S.C., Gillespie G.Y., Whitley R.J. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. Journal of Virology 2012, 86:5304-5313.
79. Martin D., Galisteo R., Gutkind J.S. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. Journal of Biological Chemistry 2009, 284:6038-6042.
80. Mena A.C., Pulido E.G., Guillen-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 2010, 21(Suppl. 1):S3-S11.
81. Nabors L.B., Fiveash J.B., Markert J.M., Kekan M.S., Gillespie G.Y., Huang Z., Johnson M.J., Meleth S., Kuo H., Gladson C.L., Fathallah-Shaykh H.M. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Archives of Neurology 2010, 67:313-319.
82. Nakagawa T., Kubota T., Kabuto M., Sato K., Kawano H., Hayakawa T., Okada Y. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. Journal of Neurosurgery 1994, 81:69-77.
83. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Research 2000, 60:2497-2503.
84. Niola F., Evangelisti C., Campagnolo L., Massalini S., Bue M.C., Mangiola A., Masotti A., Maira G., Farace M.G., Ciafre S.A. A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biology and Therapy 2006, 5:174-179.
85. Nishimori H., Shiratsuchi T., Urano T., Kimura Y., Kiyono K., Tatsumi K., Yoshida S., Ono M., Kuwano M., Nakamura Y., Tokino T. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 1997, 15:2145-2150.
86. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
87. Ohlfest J.R., Demorest Z.L., Motooka Y., Vengco I., Oh S., Chen E., Scappaticci F.A., Saplis R.J., Ekker S.C., Low W.C., Freese A.B., Largaespada D.A. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Molecular Therapy 2005, 12:778-788.
88. Patel M.M., Goyal B.R., Bhadada S.V., Bhatt J.S., Amin A.F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 2009, 23:35-58.
89. Perollet C., Han Z.C., Savona C., Caen J.P., Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 1998, 91:3289-3299.
90. Perri S.R., Nalbantoglu J., Annabi B., Koty Z., Lejeune L., Francois M., Di Falco M.R., Beliveau R., Galipeau J. Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Research 2005, 65:8359-8365.
91. Pfeifer A., Kessler T., Silletti S., Cheresh D.A., Verma I.M. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:12227-12232.
92. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., Misra A., Nigro J.M., Colman H., Soroceanu L., Williams P.M., Modrusan Z., Feuerstein B.G., Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
93. Pulkkanen K.J., Laukkanen J.M., Fuxe J., Kettunen M.I., Rehn M., Kannasto J.M., Parkkinen J.J., Kauppinen R.A., Pettersson R.F., Yla-Herttuala S. The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Therapy 2002, 9:908-916.
94. Read T.A., Farhadi M., Bjerkvig R., Olsen B.R., Rokstad A.M., Huszthy P.C., Vajkoczy P. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Research 2001, 61:6830-6837.
95. Ribatti D., Vacca A., Presta M. The discovery of angiogenic factors: a historical review. General Pharmacology 2000, 35:227-231.
96. Ribatti D., Vacca A., Roncali L., Dammacco F. The chick embryo chorioallantoic membrane as a model for in vivo research on anti-angiogenesis. Current Pharmaceutical Biotechnology 2000, 1:73-82.
97. Ribatti D., Vacca A., Roncali L., Dammacco F., Hematopoiesis angiogenesis: a link between two apparently independent processes. Journal of Hematotherapy and Stem Cell Research 2000, 9:13-19.
98. Rini B.I., Rathmell W.K. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clinical Cancer Research 2007, 13:741s-746s.
99. Roche F.P., Sheahan B.J., O'Mara S.M., Atkins G.J. Semliki forest virus-mediated gene therapy of the RG2 rat glioma. Neuropathology and Applied Neurobiology 2010, 36:648-660.
100. Rolle K., Nowak S., Wyszko E., Nowak M., Zukiel R., Piestrzeniewicz R., Gawronska I., Barciszewska M.Z., Barciszewski J. Promising human brain tumors therapy with interference RNA intervention (iRNAi). Cancer Biology and Therapy 2010, 9:396-406.
101. Ryu C.H., Park S.H., Park S.A., Kim S.M., Lim J.Y., Jeong C.H., Yoon W.S., Oh W.I., Sung Y.C., Jeun S.S. Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. Human Gene Therapy 2011, 22:733-743.
102. Saeki Y., Fraefel C., Ichikawa T., Breakefield X.O., Chiocca E.A. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Molecular Therapy 2001, 3:591-601.
103. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., Corfas G., Folkman J. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nature Medicine 2004, 10:255-261.
104. Sathornsumetee S., Cao Y., Marcello J.E., Herndon J.E., McLendon R.E., Desjardins A., Friedman H.S., Dewhirst M.W., Vredenburgh J.J., Rich J.N. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. Journal of Clinical Oncology 2008, 26:271-278.
105. Shichinohe T., Bochner B.H., Mizutani K., Nishida M., Hegerich-Gilliam S., Naldini L., Kasahara N. Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Therapy 2001, 8:879-889.
106. Sleijfer S., Ray-Coquard I., Papai Z., Le Cesne A., Scurr M., Schoffski P., Collin F., Pandite L., Marreaud S., De Brauwer A., van Glabbeke M., Verweij J., Blay J.Y., Pazopanib a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). Journal of Clinical Oncology 2009, 27:3126-3132.
107. Streck C.J., Dickson P.V., Ng C.Y., Zhou J., Hall M.M., Gray J.T., Nathwani A.C., Davidoff A.M. Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta. Cancer Gene Therapy 2006, 13:99-106.
108. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005, 352:987-996.
109. Sulpice E., Contreres J.O., Lacour J., Bryckaert M., Tobelem G. Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms. European Journal of Biochemistry 2004, 271:3310-3318.
110. Suzuki M., Chiocca E.A., Saeki Y. Stable transgene expression from HSV amplicon vectors in the brain: potential involvement of immunoregulatory signals. Molecular Therapy 2008, 16:1727-1736.
111. Szentirmai O., Baker C.H., Bullain S.S., Lin N., Takahashi M., Folkman J., Mulligan R.C., Carter B.S. Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation. Journal of Neurosurgery 2008, 108:979-988.
112. Tahara H., Lotze M.T. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Therapy 1995, 2:96-106.
113. Takano S., Yamashita T., Ohneda O. Molecular therapeutic targets for glioma angiogenesis. Journal of Oncology 2010, 2010:351908.
114. Takano S., Yoshii Y., Kondo S., Suzuki H., Maruno T., Shirai S., Nose T. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Research 1996, 56:2185-2190.
115. Tanaka T., Manome Y., Wen P., Kufe D.W., Fine H.A. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Medicine 1997, 3:437-442.
116. Tandle A., Blazer D.G., Libutti S.K. Antiangiogenic gene therapy of cancer: recent developments. Journal of Translational Medicine 2004, 2:22.
117. Templeton N.S. Nonviral delivery for genomic therapy of cancer. World Journal of Surgery 2009, 33:685-697.
118. Thaci B., Ulasov I.V., Wainwright D.A., Lesniak M.S. The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget 2011, 2:113-121.
119. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nature Reviews Genetics 2003, 4:346-358.
120. Thorne S.H., Tam B.Y., Kirn D.H., Contag C.H., Kuo C.J. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. Molecular Therapy 2006, 13:938-946.
121. van Eekelen M., Sasportas L.S., Kasmieh R., Yip S., Figueiredo J.L., Louis D.N., Weissleder R., Shah K. Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene 2010, 29:3185-3195.
122. Veerhuis R., Nielsen H.M., Tenner A.J. Complement in the brain. Molecular Immunology 2011, 48:1592-1603.
123. Visted T., Bjerkvig R., Enger P.O. Cell encapsulation technology as a therapeutic strategy for CNS malignancies. Neuro-Oncology 2001, 3:201-210.
124. Volpert O.V., Dameron K.M., Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997, 14:1495-1502.
125. Wade-Martins R., Saeki Y., Chiocca E.A. Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Molecular Therapy 2003, 7:604-612.
126. Wade-Martins R., Smith E.R., Tyminski E., Chiocca E.A., Saeki Y. An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nature Biotechnology 2001, 19:1067-1070.
127. Wakimoto H., Fulci G., Tyminski E., Chiocca E.A. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Therapy 2004, 11:214-223.
128. Wakimoto H., Johnson P.R., Knipe D.M., Chiocca E.A. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Therapy 2003, 10:983-990.
129. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K.E., Geber A., Fligelman B., Leversha M., Brennan C., Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
130. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 2004, 64:7099-7109.
131. Xiao X.R., Kang X.X., Zhao J.Z. [Therapeutic effect of brain-specific angiogenesis inhibitor 1 on glioblastoma: an animal experiment]. Zhonghua Yi Xue Za Zhi 2006, 86:1342-1346.
132. Yamanaka R., Tanaka R., Yoshida S., Saitoh T., Fujita K. Growth inhibition of human glioma cells modulated by retrovirus gene transfection with antisense IL-8. Journal of Neuro-Oncology 1995, 25:59-65.
133. Yanamandra N., Kondraganti S., Gondi C.S., Gujrati M., Olivero W.C., Dinh D.H., Rao J.S. Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. International Journal of Cancer 2005, 115:998-1005.
134. Yang C.T., Lin Y.C., Lin C.L., Lu J., Bu X., Tsai Y.H., Jia W.W. Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Research 2005, 25:2049-2054.
135. Yang S.Y., Liu H., Zhang J.N. Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12. DNA and Cell Biology 2004, 23:381-389.
136. Yin J., Kim J.K., Moon J.H., Beck S., Piao D., Jin X., Kim S.H., Lim Y.C., Nam D.H., You S., Kim H., Choi Y.J. hMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. Molecular Therapy 2011, 19:1161-1169.
137. Yoo J.Y., Haseley A., Bratasz A., Chiocca E.A., Zhang J., Powell K., Kaur B. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and Vstat120-expressing oncolytic virus. Molecular Therapy 2012, 20:287-297.
138. Yoo J.Y., Kim J.H., Kim J., Huang J.H., Zhang S.N., Kang Y.A., Kim H., Yun C.O. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Therapy 2008, 15:635-651.
139. Yoo J.Y., Kim J.H., Kwon Y.G., Kim E.C., Kim N.K., Choi H.J., Yun C.O. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Molecular Therapy 2007, 15:295-302.
140. Yoshida D., Kim K., Noha M., Teramoto A. Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells. Journal of Neuro-Oncology 2006, 76:13-21.
141. Youn J.I., Park S.H., Jin H.T., Lee C.G., Seo S.H., Song M.Y., Lee C.W., Sung Y.C. Enhanced delivery efficiency of recombinant adenovirus into tumor and mesenchymal stem cells by a novel PTD. Cancer Gene Therapy 2008, 15:703-712.
142. Yu C., Friday B.B., Lai J.P., Yang L., Sarkaria J., Kay N.E., Carter C.A., Roberts L.R., Kaufmann S.H., Adjei A.A. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Molecular Cancer Therapeutics 2006, 5:2378-2387.
143. Yun J., Sonabend A.M., Ulasov I.V., Kim D.H., Rozhkova E.A., Novosad V., Dashnaw S., Brown T., Canoll P., Bruce J.N., Lesniak M.S. A novel adenoviral vector labeled with superparamagnetic iron oxide nanoparticles for real-time tracking of viral delivery. Journal of Clinical Neuroscience 2012, 19:875-880.
144. Zagzag D., Friedlander D.R., Dosik J., Chikramane S., Chan W., Greco M.A., Allen J.C., Dorovini-Zis K., Grumet M., Tenascin C. expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Research 1996, 56:182-189.
145. Zagzag D., Friedlander D.R., Miller D.C., Dosik J., Cangiarella J., Kostianovsky M., Cohen H., Grumet M., Greco M.A. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Research 1995, 55:907-914.
146. Zhang Y., Satterlee A., Huang L. In vivo gene delivery by nonviral vectors: overcoming hurdles?. Molecular Therapy 2012.
147. Zhu G., Su W., Jin G., Xu F., Hao S., Guan F., Jia W., Liu F. Glioma stem cells targeted by oncolytic virus carrying endostatin-angiostatin fusion gene and the expression of its exogenous gene in vitro. Brain Research 2011, 1390:59-69.